Docetaxel Plus Bevacizumab in Pretreated, Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC
Docetaxel is and an effective cytotoxic agent in > 1st line treatment of advanced or
metastatic non small cell lung cancer (NSCLC). Recently, a phase III study of 1st line
treatment in patients with advanced or metastatic NSCLC showed that the addition of
bevacizumab to a platinum-based regimen provided a survival benefit. There are patients with
NSCLC who have not received bevacizumab and have relapsed after 1st and/or 2nd line therapy.
The evaluation of bevacizumab plus chemotherapy in such patients is justified. This study
will evaluate the combination of docetaxel and bevacizumab as 2nd or 3rd line treatment of
NSCLC.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Progression Free Survival
1 year
No
Lampros Vamvakas, MD
Principal Investigator
University Hospital of Crete, Dep of Medical Oncology
Greece: National Organization of Medicines
CT/08.09
NCT00741195
April 2008
March 2013
Name | Location |
---|